ELI (Elsohly Laboratories, Incorporated)

ELI (Elsohly Laboratories, Incorporated), doing business as E L I, is a for-profit manufacturer and research organization specializing in the analysis and evaluation of cannabinoids, particularly synthetic variants like D-8-THC. Registered to receive federal contract and grant awards since January 17, 2003, E L I provides a range of services to the federal government, including blind drug samples, welcome kits, and conducting research related to drug development and pharmacology. As a subchapter S corporation, E L I demonstrates capabilities in both manufacturing goods and conducting scientific research for various federal agencies, positioning itself as a valuable partner in drug-related studies and product development.

Through federal contract awards, E L I has secured prime contracts from multiple civilian agencies, showcasing its versatility in meeting diverse government needs. The company was awarded a $152,280 firm fixed-price purchase order contract by the Department of Veterans Affairs to provide blind drug samples, with an estimated completion date of October 14, 2027. This contract highlights E L I's expertise in producing specialized pharmaceutical samples for research and testing purposes. Additionally, E L I supplied welcome kits to the U.S. Embassy in Bangui under a separate purchase order contract, demonstrating its ability to fulfill logistical and supply chain requirements for government agencies. As a subcontractor, E L I has fulfilled multiple purchase orders for Research Triangle Institute, likely related to drug research and development. These contract awards did not have set-aside designations, indicating that E L I competed in full and open competition for these opportunities, further underscoring its competitiveness in the federal contracting arena.

In the realm of federal grants, E L I has received significant funding to support its research initiatives, particularly in the field of cannabinoid research and drug development. Most notably, the National Institute on Drug Abuse, part of the National Institutes of Health, awarded E L I a $198,912 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). This two-year grant, commencing on April 15, 2024, funds E L I's research on isolating and pharmacologically evaluating impurities found in synthetic D-8-THC products. The project aims to scale up isolation processes, assess binding affinity and potency of impurities, and determine their interactions with D-8-THC, contributing valuable insights to the field of cannabinoid pharmacology. E L I has also participated as a sub-grantee in a project titled "New Drug Leads for Resistant Visceral Leishmaniasis" with Southern Research Institute as the prime grantee. This collaboration demonstrates E L I's involvement in diverse areas of drug research and development, extending beyond cannabinoids to include tropical disease treatments, and highlights the company's ability to work effectively as both a prime recipient and subrecipient of federal grant funding.